Soterix Medical

Soterix Medical

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $4.3M

Overview

Soterix Medical is a private, revenue-generating medical device company focused on the neuroscience and neuromodulation sector. Its core business is providing high-precision, research-grade hardware (e.g., tDCS, HD-tES, TMS, tFUS devices) and sophisticated neurotargeting software to academic, clinical, and research institutions globally. The company has built a comprehensive portfolio that spans from foundational 1x1 tDCS systems to cutting-edge platforms like Temporal Interference Stimulation for deep brain targets, alongside synergistic monitoring technologies like EEG and fNIRS. Its strategy involves supporting the scientific community with tools for clinical trials and human performance testing while developing user-friendly solutions for clinical treatment.

NeurosciencePsychiatry

Technology Platform

Integrated ecosystem of non-invasive neuromodulation hardware (tDCS, HD-tES, TMS, tFUS, TI) and brain monitoring technologies (EEG, fNIRS), coupled with proprietary neurotargeting and electric field modeling software for personalized stimulation.

Funding History

2
Total raised:$4.3M
Grant$1.8M
Grant$2.5M

Opportunities

The growing neuromodulation market and shift towards non-invasive therapies and digital health create significant demand for research-grade and clinically deployable devices.
Expansion into decentralized clinical trials via the REMOTE platform and the potential for regulatory clearances for specific tES indications could open large therapeutic markets.

Risk Factors

Regulatory and reimbursement hurdles for clinical adoption pose significant risks.
The company faces competition from larger medical device firms and relies on the broader scientific success of neuromodulation therapies, which could be setback by negative clinical trial results.

Competitive Landscape

Soterix competes in specialized segments against companies like Neuroelectrics (tES), MagVenture & Brainsway (TMS), and various fNIRS/EEG manufacturers. Its differentiation lies in its comprehensive multi-modal platform, strong focus on research, and advanced neurotargeting software, though it faces larger competitors with greater commercial scale in therapeutic markets.